share_log

HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $38 Price Target

Benzinga ·  Apr 24 01:28

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintains $38 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment